|Strain Name||C57BL/6-Tigittm1(hTIGIT)/Bcgen||Common Name||B-hTIGIT mice|
|Catalog number (Males)||BCM031M||Catalog number (Females)||BCM031F|
|Related Genes||Tigit (T cell immunoreceptor with Ig and ITIM domains)|
TIGIT (T-cell immunoreceptor with Ig and ITIM domains), a member of the immunoglobulin family of PVR (poliovirus receptor), is a type I transmembrane protein. Similar to PD-1, TIM3, and L AG3, TIGIT is highly expressed in cancer tissues and competitively binds to TIGIT receptors with DNAM-1 proteins on the surface of NK cells to reduce the NK cell killing efficiency of cancer cells. Therefore, anti-TIGIT antibody can enhance NK cell ability to destroy tumor cells by facilitating DNAM-1 binding to TIGIT receptors. It has become the new generation of cancer immunotherapy checkpoint.
mRNA expression analysis
Fig 1. RT-PCR analysis of TIGIT gene.
The hTIGIT, but not mTIGIT, mRNA was detected in splenocytes of the homozygous B-hTIGIT mice.
Protein expression analysis
Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hTIGIT mice were analyzed by flow cytometry.
Mouse TIGIT+ T cells were detected in the WT mice, while human TIGIT+ T cells were detected in the homozygous B-hTIGIT mice.
TIGIT Ab efficacy evaluation
Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hTIGIT mice. Mice were divided into control and treatment groups (n = 5) when the tumor volume was about 100 mm3. The anti-human TIGIT antibody inhibits tumor growth in the homozygous B-hTIGIT mice, suggesting that the B-hTIGIT mouse model is an effective tool for in vivo hTIGIT antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.